401 related articles for article (PubMed ID: 27845387)
61. Porcine Zygote Injection with Cas9/sgRNA Results in DMD-Modified Pig with Muscle Dystrophy.
Yu HH; Zhao H; Qing YB; Pan WR; Jia BY; Zhao HY; Huang XX; Wei HJ
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27735844
[TBL] [Abstract][Full Text] [Related]
62. Generation of a DMD loss-of-function mutant human embryonic stem cell lines by CRISPR base editing.
Jin H; Fu H; Wang J; Wang Z; Liu J; Han F; Zheng H; Jiang Y
Stem Cell Res; 2024 Apr; 76():103343. PubMed ID: 38428348
[TBL] [Abstract][Full Text] [Related]
63. Challenges associated with homologous directed repair using CRISPR-Cas9 and TALEN to edit the DMD genetic mutation in canine Duchenne muscular dystrophy.
Mata López S; Balog-Alvarez C; Vitha S; Bettis AK; Canessa EH; Kornegay JN; Nghiem PP
PLoS One; 2020; 15(1):e0228072. PubMed ID: 31961902
[TBL] [Abstract][Full Text] [Related]
64. Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases.
Ousterout DG; Kabadi AM; Thakore PI; Perez-Pinera P; Brown MT; Majoros WH; Reddy TE; Gersbach CA
Mol Ther; 2015 Mar; 23(3):523-32. PubMed ID: 25492562
[TBL] [Abstract][Full Text] [Related]
65. CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy.
Wang DN; Wang ZQ; Jin M; Lin MT; Wang N
Gene Ther; 2022 Dec; 29(12):730-737. PubMed ID: 35534612
[TBL] [Abstract][Full Text] [Related]
66. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
Nik-Ahd F; Bertoni C
Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
[TBL] [Abstract][Full Text] [Related]
67. CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice.
Xu L; Park KH; Zhao L; Xu J; El Refaey M; Gao Y; Zhu H; Ma J; Han R
Mol Ther; 2016 Mar; 24(3):564-9. PubMed ID: 26449883
[TBL] [Abstract][Full Text] [Related]
68. In vivo gene editing in dystrophic mouse muscle and muscle stem cells.
Tabebordbar M; Zhu K; Cheng JKW; Chew WL; Widrick JJ; Yan WX; Maesner C; Wu EY; Xiao R; Ran FA; Cong L; Zhang F; Vandenberghe LH; Church GM; Wagers AJ
Science; 2016 Jan; 351(6271):407-411. PubMed ID: 26721686
[TBL] [Abstract][Full Text] [Related]
69. Genome editing for Duchenne muscular dystrophy: a glimpse of the future?
Kupatt C; Windisch A; Moretti A; Wolf E; Wurst W; Walter MC
Gene Ther; 2021 Sep; 28(9):542-548. PubMed ID: 33531685
[TBL] [Abstract][Full Text] [Related]
70. Effective regeneration of dystrophic muscle using autologous iPSC-derived progenitors with CRISPR-Cas9 mediated precise correction.
Hagan M; Ashraf M; Kim IM; Weintraub NL; Tang Y
Med Hypotheses; 2018 Jan; 110():97-100. PubMed ID: 29317080
[TBL] [Abstract][Full Text] [Related]
71. High-capacity adenovector delivery of forced CRISPR-Cas9 heterodimers fosters precise chromosomal deletions in human cells.
Tasca F; Brescia M; Liu J; Janssen JM; Mamchaoui K; Gonçalves MAFV
Mol Ther Nucleic Acids; 2023 Mar; 31():746-762. PubMed ID: 36937620
[TBL] [Abstract][Full Text] [Related]
72. Comparison of In-Frame Deletion, Homology-Directed Repair, and Prime Editing-Based Correction of Duchenne Muscular Dystrophy Mutations.
Zhao X; Qu K; Curci B; Yang H; Bolund L; Lin L; Luo Y
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238739
[TBL] [Abstract][Full Text] [Related]
73. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
Jarmin S; Kymalainen H; Popplewell L; Dickson G
Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
[TBL] [Abstract][Full Text] [Related]
74. Toward the correction of muscular dystrophy by gene editing.
Olson EN
Proc Natl Acad Sci U S A; 2021 Jun; 118(22):. PubMed ID: 34074727
[TBL] [Abstract][Full Text] [Related]
75. CRISPR-Based Therapeutic Gene Editing for Duchenne Muscular Dystrophy: Advances, Challenges and Perspectives.
Chen G; Wei T; Yang H; Li G; Li H
Cells; 2022 Sep; 11(19):. PubMed ID: 36230926
[TBL] [Abstract][Full Text] [Related]
76. Reading frame correction by targeted genome editing restores dystrophin expression in cells from Duchenne muscular dystrophy patients.
Ousterout DG; Perez-Pinera P; Thakore PI; Kabadi AM; Brown MT; Qin X; Fedrigo O; Mouly V; Tremblay JP; Gersbach CA
Mol Ther; 2013 Sep; 21(9):1718-26. PubMed ID: 23732986
[TBL] [Abstract][Full Text] [Related]
77. Duchenne muscular dystrophy: CRISPR/Cas9 treatment.
Mendell JR; Rodino-Klapac LR
Cell Res; 2016 May; 26(5):513-4. PubMed ID: 26926391
[TBL] [Abstract][Full Text] [Related]
78. Generation of human induced pluripotent stem cell line derived from Becker muscular dystrophy patient with CRISPR/Cas9-mediated correction of DMD gene mutation.
Przymuszała M; Martyniak A; Kwiatkowska J; Meyer-Szary J; Śledzińska K; Wierzba J; Dulak J; Florczyk-Soluch U; Stępniewski J
Stem Cell Res; 2024 Apr; 76():103327. PubMed ID: 38324931
[TBL] [Abstract][Full Text] [Related]
79. Gene correction of a duchenne muscular dystrophy mutation by meganuclease-enhanced exon knock-in.
Popplewell L; Koo T; Leclerc X; Duclert A; Mamchaoui K; Gouble A; Mouly V; Voit T; Pâques F; Cédrone F; Isman O; Yáñez-Muñoz RJ; Dickson G
Hum Gene Ther; 2013 Jul; 24(7):692-701. PubMed ID: 23790397
[TBL] [Abstract][Full Text] [Related]
80. In-Frame Deletion of Dystrophin Exons 8-50 Results in DMD Phenotype.
Egorova TV; Galkin II; Velyaev OA; Vassilieva SG; Savchenko IM; Loginov VA; Dzhenkova MA; Korshunova DS; Kozlova OS; Ivankov DN; Polikarpova AV
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
